Epigenomics AG, DE000A3H2184

Epigenomics AG, DE000A3H2184

19.09.2022 - 07:03:29

EQS-News: Epigenomics Initiates prospective multi-center clinical trial for ?Next-Generation? blood-based colorectal cancer test

19.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at www.eqs-news.com

Language: English Company: Epigenomics AG Geneststra?e 5 10829 Berlin

Germany Phone: +49 30 24345-0 Fax: +49 30 24345-555 E-mail: ir@epigenomics.com Internet: www.epigenomics.com ISIN: DE000A3H2184 WKN: A3H218 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1444775 ? End of News EQS News Service

1444775??19.09.2022?CET/CEST

@ dgap.de